ADAM9 and lung carcinoma: However, CDCP1 levels and EGFR signaling, as indicated by phospho-EGFR expression, were dampened in ADAM9-knockdown lung cancer cells, and ADAM9-knockdown cells showed more sensitivity to EGFR inhibitor treatment (Tarceva) than control cells (shGFP) (Figure 7A and 7B).